EMCDDA; March 2023
Tag: EMCDDA
EU Drug Market: Methamphetamine — In-depth analysis
EMCDDA and Europol; 56pp; 2022
Recreational use of nitrous oxide: a growing concern for Europe
Leon Van Aerts, Joanna de Morais, Michael Evans-Brown, Rita Jorge, Ana Gallegos, Rachel Christie, Thomas Néfau, Gregorio Planchuelo, Roumen Sedefov
EMCDDA; 86pp; 2022
Complexity and differentiation of the MDMA retail market: insights from the European Web Survey on Drugs
Comparing two approaches for estimating cannabis consumption: raking and regression
Jonathan P. Caulkins, Kyle Furlong, Brandon McComas, Martha Nogueira Domingues, Aatir Siddique and Beau Kilmer
EMCDDA; 2022
Sources of cannabis acquisition by country and frequency of use in the European web survey on drugs
New psychoactive substances: 25 years of early warning and response in Europe — an update from the EU Early Warning System
EMCDDA; 38pp; June 2022
New benzodiazepines in Europe – a review
EMCDDA; 48pp; 2021
3-CMC: Report on the risk assessment of 1-(3-chlorophenyl)-2-(methylamino)propan-1-one (3-chloromethcathinone, 3-CMC) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended)
EMCDDA; 90pp; 2022
3-MMC: Report on the risk assessment of 2-(methylamino)-1-(3-methylphenyl)propan-1-one (3-methylmethcathinone, 3-MMC) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended)
EMCDDA; 2022
Methamphetamine from Afghanistan: signals indicate that Europe should be better prepared
European Monitoring Centre for Drugs and Drug Addiction; September 2021
Synthetic cannabinoids in Europe – a review
V. Auwärter, J. de Morais, A. Gallegos, M. Evans-Brown, R. Christie, R. Jorge, R. Sedefov
European Monitoring Centre for Drugs and Drug Addiction; September 2021